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Thapsigargin is a potent inhibitor of the microsomal calcium-ATPase. We hypothesized that thapsigargin-induced liberation of calcium from 
sequestered intracellular sites could result in irreversible brain injury. To assess neurotoxicity, intracerebral injections of 0.1 100 nmol thapsigargin 
were performed in 7-day-old rats, and the severity of injury was assessed 5 days later by microscopy and measurements ot"lesioncd areas. We found 
that thapsigargin elicited dose-dependent tissue injury in perinatal rodent brain. 
Thapsigargin, an inhibitor of the microsomal calcium- 
ATPase, has proven to be a valuable agent for study of 
the regulation of calcium homeostasis in vitro [7, 8, 11, 
14 16]. It is a plant-derived sesquiterpene lactone, and a 
(non-phorboid) tumor promoter that releases intracellu- 
lar calcium stores in many cell types. Thapsigargin stim- 
ulates release of intracellular calcium both from micro- 
somal pools sensitive to inositol 1,4,5-trisphosphate 
(IP3), and also from stores that are unaffected by IP~ [1]. 
In rat brain-derived microsomes, 10 nM thapsigargin 
maximally inhibited ATP-dependent calcium accumula- 
tion [16]. In cultured hepatocytes, exposure to 200 nM 
thapsigargin elicited rapid and sustained increases in free 
intracellular calcium concentration ([Ca2+]i) [6]. In cul- 
tured muscle cells, 30-rain exposure to thapsigargin in- 
hibited cell division and suppressed DNA and protein 
synthesis, but did not alter cell viability or morphology 
[4]. The in vivo actions of this drug have not been re- 
ported. 
Since increased free [Ca2+]i may play a pivotal role in 
the pathogenesis of neuronal injury, we hypothesized 
that thapsigargin could be a useful agent for study of 
calcium-mediated brain injury in vivo. Since developing 
neurons may be particularly susceptible to calcium over- 
load because of immaturity ofintracellular buffering sys- 
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tems (e.g. calcium binding proteins such as calbindin 
[13]), we tested the neurotoxicity of thapsigargin by in- 
jecting this compound intracerebrally in 7-day-old rats. 
On post-natal day (PND) 7, rats (Sprague-Dawley, 
Charles River) were anesthetized with ether. Thapsi- 
gargin was injected stereotactically into right posterior 
striatum, using previously described methods [10]. In 
brief, animals were positioned in a Kopf small animal 
stereotaxic apparatus, a mid-line scalp incision was 
made, and bregma was used as a surface landmark to 
determine the injection site (coordinates: AP -2  mm, L 
2.5 mm~ D 4 mm). The skull was penetrated with a 22- 
gauge needle, and thapsigargin (dissolved in 1 ¢tl DMSO) 
was injected slowly with a Hamilton syringe (doses 
tested: 0.1~ 0.5~ 1~ 10, 25, 50 and 100 nmol, n=3 5/group). 
Six control animals received injections of equal volumes 
of DMSO. The majority of animals that received ->25 
nmol thapsigargin died acutely. Overall, 15 thapsigargin- 
injected animals survived to PND 12: they were killed by 
decapitation, and brains were removed intact and rap- 
idly frozen. The surgical protocol was approved by the 
University of Michigan Animal Care and Use Commit- 
tee. 
20-¢tm coronal frozen brain sections were prepared, 
post-fixed with paraformaldehyde and stained for Nissl 
substance with Cresyl violet. To quantitate the severity 
of tissue injury, an image analyzer (MC1D, Imaging Re- 
search Inc., St. Catherines, Ont.) was used to estimate the 
extent of injury in each brain. Areas in which Nissl-stain- 
ing was disrupted were identified~ outlined with a cursor, 
Fig. 1. Photographs of Nissl-stained coronal brain sections, prepared l¥om PND 12 animals that had received intracerebral injections of DMSO (A) 
or thapsigargin (0.1 (B), 0.5 (C), 1 (D), 10 (E) or 25 (F) nmol) oil PND 7 (see text for Methodsl. These photographs demonstrate the histopathologic 
features of thapsigargin-induced lesions. In the DMSO-injected animal IA), there are subtle lesions in the pyramidal cell layer along the rejection track 
(arrowheads). In the brains from animals that received thapsigargin, lesions of increasing severity are apparent. The lowest dose tested (B) elicited 
subtle lesions in the pyramidal cell layer, similar to those elicited by DMSO: administration of 0.5 nmol ((171 elicited more extensive injury, with 
prominent loss of dentate gyrus and CA4 neurons in the example shown (arrowheads). With higher doses, injury also extended into the overlying 
corpus callosum (D,E). In a single animal that survived for 5 days after receiving 25 nmol thapsigargin (F), there was widespread tissue injury, with 
obliteration of major anatomic landmarks. 
and measured ( - 1 0  sections/brain, close to the region of 
maximum injury) and group means were calculated. 
With our injection methods, if saline is administered, 
the needle track can sometimes be identified (distortion 
or disruption of  cellular integrity along the injection 
track, most  evident in the hippocampal pyramidal cell 
layer). In 4/6 DMSO-injected animals, focal cell loss ad- 
jacent to the injection track was detected (as in Fig. I A) 
and in 2/6 injury extended up to 2 mm from the track. In 
all surviving thapsigargin-lesioned animals, there was ev- 
idence of  brain injury, extending to a variable degree 
from the injection site (Fig. 1 B-F). In the 3 animals that 
received the lowest dose of  thapsigargin (0.1 nmol), there 
was discrete cell loss in the pyramidal cell layer adjacent 
to the injection site (Fig. IB); in 1/3, the hippocampus 
was distorted and there was enlargement of  the adjacent 
lateral ventricle (area of  injury measurements could not 
be reliably obtained from this brain). In all animals that 
received doses of  thapsigargin ->0.5 nmol there was more 
widespread tissue injury extending from the injection 
site. At higher doses, in addition to prominent neuronal 
loss, there was cystic necrosis of  overlying corpus callo- 
sum (as in Fig. 1D,E). At the highest dose tested compat-  
ible with survival (25 nmol), there was massive necrosis 
and complete disruption of tissue integrity (Fig. IF). Fig. 
2 compares the areas of  the lesions in animals that re- 
ceived 0.1 25 nmol thapsigargin: the extent of  injury in- 
creased with higher doses (r2=0.81, P=0.0001, regression 
analysis). 
Variations in the sites of  maximal injury were readily 
attributable to slight differences in the accuracy of  needle 
placement. In instances where the injection site was, in- 
advertently, displaced either medially or laterally, the 
histologic features and size of  the resulting lesions were 
similar. There was no apparent regional or cellular selec- 
tivity in the distribution of injury. In the hippocampus, 
for example, CA1 and CA3 pyramidal cells and dentate 
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Fig. 2. This graph compares the extent of brain injury that resulted after 
intracerebral injections of 0.1, 0.5, I, 10 or 25 nmol thapsigargin (see 
text for Methods). Animals were lesioned on PND 7. and histopathol- 
ogy was assessed on PND 12 (n-2  5/group, except for 25 nmol, n - l ) .  
Coronal brain sections were prepared and Nissl-stained. The site of 
maximal injury was identified, and the area of injury was outlined and 
measured in at least 10 sections/brain, close to this site, using a compu- 
terized image analysis system {MCID, Imaging Resources, St. Cather- 
ines, Ont.). Values are expressed as mean+S.E.M. (except for 25 nmol, 
n - l ) ;  note that y-axis is logarithmic. *, indicates r-" 0.81, P-O.O001, 
regression analysis, comparing doses of thapsigargin administered and 
areas of  injury. 
Similarly, there was no apparent sparing of white matter 
tracts, and more severe lesions encompassed corpus cal- 
losum. At higher doses, the lesions extended into poste- 
rior striatum and thalamus. 
Our results indicate that thapsigargin is a potent neu- 
rotoxin in perinatal rodent brain. In vitro thapsigargin 
effectively inhibits Ca-ATPase at sub-nanomolar con- 
centrations [11]. Although the thapsigargin concentra- 
tion attained in brain tissue is difficult to estimate accu- 
rately, the in vivo toxic effects were observed in a similar 
range. There are no data about the pharmacokinetics of 
thapsigargin and it is impossible to predict the likely du- 
ration of exposure to the compound after intracerebral 
injection. If thapsigargin blocked microsomal Ca -̀+ up- 
take and intracellular calcium buffering and sequestra- 
tion mechanisms were inadequate to compensate, stis- 
tained elevations in free [Ca>]i could result. In addition, 
there is evidence of functional coupling between intracel- 
lular Ca > pools and the permeability of the plasma 
membrane to Ca > in neuronal cells; depletion of intra- 
cellular pools could increase plasma membrane Ca > per- 
meability, and thereby lead to further increases in free 
[Ca2+]i [8, 14]. [Ca>]i was not measured in lesioned tissue, 
and the possibility that an unrecognized mechanism of 
action, rather than Ca > mobilization, was responsible 
for thapsigargin's toxicity cannot be excluded. Yet, it is 
readily conceivable that brain injury did result from the 
deleterious effects of elevated free [Ca>],. 
Considerable data indicate that increased free [Ca-~ ']~ is 
an important mediator of ischemic and excitotoxic brain 
injury [2, 3, 5, 9, 12]. The pathophysiologic factors that 
contribute to the rise in free [Ca-'-]~ with these types of 
injury include increased influx (through both voltage- 
and neurotransmitter-gated channels), release from 
metabolically compromised mitochondria, and in some 
cell types suppression of the sodium-dependent calcium 
exchanger. Whether pathologic increases in the amount 
of Ca > released from microsomal stores occur in these 
settings is unknown. Potential deleterious effects of ele- 
vated free [Ca:+]1 include activation of multiple degrada- 
tive enzymes, uncoupling of oxidative phosphorylation 
and energy depletion: at what point these events induce 
irreversible neuronal injury and the factors that deter- 
mine cellular differences in susceptibility remain un- 
known. 
One of the most surprising features of the histopathol- 
ogic distribution of injury was its uniformity. The neu- 
ronal populations examined (in hippocampal pyramidal 
cell layer and dentate gyms, striatum, cortex and thala- 
mus) and white matter tracts, all appeared equally sus- 
ceptible to injury. Some degree of cellular or regional 
selectivity might be detectable if doses close to the toxic- 
ity threshold or different intracerebral injection sites 
were tested. In vitro, the majority of studies of thapsi- 
gargin have used microsomes or permeabilized cells in 
which toxicity would be difficult to discern. Only one 
study [4] has examined the effects of thapsigargin on cel- 
lular functioning. In cultured smooth muscle ceils expo- 
sure to thapsigargin depleted the IP~-sensitive calcium 
pool but caused no morphologic changes or mitochon- 
drial dysfunction: however, cell division was completely 
blocked and DNA and protein synthesis were markedly 
suppressed. Factors accounting for the relative resis- 
tance of these cells to calcium-induced injury are uncer- 
tain: it is possible that adaptive mechanisms prevented 
sustained elevations in free [Ca~"]~ in these cells. It is also 
conceivable that the perinatal brain is particularly sus- 
ceptible to thapsigargin because of immaturity of cal- 
cium-buffering systems e.g. calbindin [17]. It will be in- 
teresting to determine if there are age-related differences 
in susceptibility to thapsigargin neurotoxicity, and if they 
can be attributed to differences in the magnitude and 
duration of increased free [Cae~]i attained. Measure- 
ments of changes in [Ca-'+]i in thapsigargin-lesioned ani- 
mals will be essential to elucidate its mechanism of neu- 
rotoxicity in vivo. 
In summary, these results indicate that thapsigargin, a 
160 
potent inhibitor of the microsomal Ca2+-ATPase, is neu- 
rotoxic in vivo in perinatal rodent brain. This drug may 
represent an important experimental tool for studying 
calcium-mediated injury in vivo, for understanding re- 
gional and developmental differences in susceptibility to 
certain forms of brain injury, and, in particular, for phar- 
macologic dissection of the potential contribution of the 
microsomal Ca 2+ pool to the evolution of neuronal in- 
jury. 
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